Definition
Barium sulfate suspension is a colloidal preparation in which finely divided barium sulfate (BaSO₄) particles are dispersed in a liquid medium, typically water or a glycerin‑based solution. The resulting opaque, white suspension is used primarily as a radiographic contrast agent for imaging the gastrointestinal (GI) tract.
Composition and Physical Properties
- Active ingredient: Barium sulfate (chemical formula BaSO₄), an insoluble inorganic compound.
- Vehicle: Aqueous or aqueous‑glycerin solution containing stabilizers (e.g., methylcellulose, carboxymethylcellulose) and flavoring agents to improve palatability.
- Particle size: Micron‑scale particles (generally 0.1–5 µm) to maintain suspension stability and ensure uniform radiopacity.
- Density: Approximately 1.4–1.5 g cm⁻³, providing sufficient attenuation of X‑rays.
- pH: Typically adjusted to near‑neutral (pH 6–8) to minimize irritation of the mucosa.
Medical Uses
- Upper GI series (barium swallow, barium meal): Patients ingest the suspension to outline the esophagus, stomach, and duodenum during fluoroscopic examination.
- Lower GI series (barium enema): The suspension is introduced into the colon via rectal catheter to delineate the colonic lumen and mucosal patterns.
- Therapeutic applications: Occasionally employed in the management of certain GI bleeding or as a protective coating in the treatment of radiation proctitis, though such uses are less common.
Administration
- Dosage: Varies with the type of study; typical adult oral doses range from 150 mL to 300 mL for an upper GI series. Enema volumes are generally 250 mL to 500 mL.
- Preparation: The suspension is shaken or stirred immediately before use to ensure homogeneity.
- Patient instructions: Patients are often advised to fast for several hours before the procedure and to follow post‑procedure positioning (e.g., left lateral decubitus) to aid in distribution and clearance.
Safety and Contraindications
- Insolubility: Barium sulfate is chemically inert and does not absorb systemically, making it safe for most patients.
- Contraindications: Known or suspected perforation of the gastrointestinal tract, ileus, severe constipation, or hypersensitivity to any component of the formulation.
- Adverse effects: May include nausea, vomiting, abdominal cramping, and, rarely, aspiration pneumonia if the suspension is inhaled.
- Precautions: In patients with suspected bowel obstruction, alternative contrast agents (e.g., water‑soluble iodinated agents) are preferred.
Regulatory Status
Barium sulfate suspensions are approved by regulatory agencies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) for diagnostic imaging. Commercial products are marketed under various trade names (e.g., Sodium Barium Suspension, Baritop), each meeting pharmacopeial standards for particle size, density, and microbial limits.
Historical Context
The use of barium sulfate as a radiopaque medium dates to the early 20th century, when its high atomic number and radiodensity were recognized as advantageous for gastrointestinal imaging. The development of stable suspensions with improved taste and texture facilitated widespread clinical adoption.
References
- National Library of Medicine. Barium sulfate suspension – Drug Information (PubMed, 2023).
- FDA. Barium Sulfate – Center for Drug Evaluation and Research (CDER) label database.
- European Pharmacopoeia, 10th Edition, Monograph on Barium Sulfate.
This entry provides a concise overview of barium sulfate suspension as a radiographic contrast agent, summarizing its composition, clinical applications, safety considerations, and regulatory status.
